ATI-052 Hits Phase 1b Endpoints in AD and Asthma; Aclaris Pivots to EoE
ACRS sits 92% above its 52-week low of $2.095.
Summary
Aclaris reported positive primary analysis results for its anti-TSLP/IL-4Rα bispecific ATI-052 in two Phase 1b proof-of-concept trials. In severe atopic dermatitis, the drug produced a 45% placebo-adjusted mean EASI change at day 57 (58% absolute vs 13% placebo) and 78% placebo-adjusted EASI-50, with itch improving 43% placebo-adjusted. In asthma, a single 480 mg dose cut FeNO 59% (45 ppb) by day 15 and improved FEV1 by 200 ml placebo-adjusted. Safety was clean: predominantly Grade 1 TEAEs, no Grade 3/4 events, no discontinuations, and no conjunctivitis — a key differentiator versus approved TSLP/IL-4Rα approaches. Management will prioritize Phase 2b development in eosinophilic esophagitis, targeting trial initiation early next year, and will update on an additional indication near term. This is the first clinical proof-of-concept readout for the company's lead bispecific and lands against a small-cap balance sheet that has leaned on ATM raises; a conference call is set for 8:00 AM ET today.
At the time of this announcement, ACRS was trading at $4.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557.9M. The 52-week trading range was $2.10 to $6.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.